(2026). Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR‐Mutated NSCLC: A Systematic Review. Cancer Medicine.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR‐Mutated NSCLC: A Systematic Review."
Cancer Medicine 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR‐Mutated NSCLC: A Systematic Review."
Cancer Medicine, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.